Skip to main content
. Author manuscript; available in PMC: 2012 Sep 9.
Published in final edited form as: Biochem Biophys Res Commun. 2011 Aug 17;412(4):737–742. doi: 10.1016/j.bbrc.2011.08.045

Table 2.

IC50 measurements and fold resistance.

Inhibitor IC50 (nM) Fold resistance Predicted resistance scorea
WT (NL4-3) MDR 769 MDR 769 82T MDR 769 MDR 769 82T MDR 769 MDR 769 82T
darunavir 0.26 ±0.024 0.74 ±0.20 2.76 ±0.16 2.8 11 10 10
tipranavir 0.24 ±0.18 0.63 ±0.17 3.02 ±0.10 2.6 13 24 64
lopinavir 0.28 ±0.27 0.50 ±0.060 3.18 ±0.23 1.8 11 76 76
amprenavir 0.43 ±0.044 4.82 ±0.90 7.87 ±0.16 11 18 86 86
atazanavir 0.19 ±0.071 2.90 ± 0.16 10.8 ±0.40 15 57 98 103
nelfinavir 1.58 ±0.85 109 ±5.0 448 ±65 69 2.8×102 184 184
ritonavir 0.34 ±0.15 60.7 ±3.5 237 ±5.6 180 7.0×102 - -
saquinavir 0.50 ±0.017 294 ±9.4 1.30×103 ±87 590 2.6×103 114 114
indinavir 0.47 ±0.19 119 ± 13 307 ±29 250 6.5×102 128 128
a

The resistance scores for darunavir, tipranavir, lopinavir, amprenavir, atazanavir, saquinavir, and indinavir were predicted based on the protease inhibitor plus ritonavir co-administration. The larger scores indicate higher predicted resistance.